Gabriel P. A. Costa, MD
Postdoctoral AssociateCards
Education
Universidade de Ribeirão Preto, Medicine (2024)
Pain and Addiction Interaction Neuroscience (PAIN) Lab
Publications Overview
- 29 Publications
- 74 Citations
- 16 Yale Co-Authors
Education
Universidade de Ribeirão Preto, Medicine (2024)
Pain and Addiction Interaction Neuroscience (PAIN) Lab
Publications Overview
- 29 Publications
- 74 Citations
- 16 Yale Co-Authors
Education
Universidade de Ribeirão Preto, Medicine (2024)
Pain and Addiction Interaction Neuroscience (PAIN) Lab
Publications Overview
- 29 Publications
- 74 Citations
- 16 Yale Co-Authors
About
Copy Link
Titles
Postdoctoral Associate
Postdoctoral Associate, Psychiatry
Biography
Dr. Gabriel Costa is a Postdoctoral Associate in the Pain and Addiction Interactions Neuroscience (PAIN) Lab at Yale University, where his research focuses on addiction psychiatry, chronic pain medicine, and cannabinoid pharmacology. With a background in both medicine and engineering, he integrates clinical research methods with advanced data science approaches to explain clinical phenomena through mechanistic human laboratory studies.
His work aims to develop novel pharmacological interventions for individuals with co-occurring opioid use disorder and chronic pain, leveraging human experimental medicine, quantitative sensory testing, pharmacokinetic/pharmacodynamic modeling, and ecological momentary assessment. Through this multidisciplinary approach, Dr. Costa seeks to inform precision treatment strategies and advance the understanding of how cannabinoids and related compounds modulate pain and addiction processes.
Appointments
Psychiatry
Postdoctoral AssociatePrimary
Other Departments & Organizations
- Pain and Addiction Interaction Neurosciences (PAIN) Lab
- Psychiatry
Education & Training
- MD
- Universidade de Ribeirão Preto, Medicine (2024)
Research
Copy Link
Overview
Public Health Interests
ORCID
0009-0007-8702-5436- View Lab Website
Pain and Addiction Interaction Neuroscience (PAIN) Lab
Research at a Glance
Yale Co-Authors
Joao P. De Aquino, MD
Julio Nunes, MD
Mehmet Sofuoglu, MD, PhD
Jeremy Weleff, DO
Brian Pittman
Ismene Petrakis, MD
Publications
2026
Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study
Costa G, Suh R, Sofuoglu M, De Aquino J. Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study. Addictive Behaviors Reports 2026, 23: 100654. DOI: 10.1016/j.abrep.2025.100654.Peer-Reviewed Original ResearchAltmetricConceptsQuantitative sensory testingOpioid use disorderPain sensitivityUse disorderProof-of-concept studyCannabidiol's impactCBD doseOpen-labelChronic painPain managementQuantitative sensory testing measuresPlacebo-controlled randomized trialPain response patternsTolerability of cannabidiolHeat pain thresholdEffects of cannabidiolAdverse cognitive effectsOpioid use disorder treatmentSensory testingPain thresholdVerbal memorySubjective effectsCannabidiol doseAdverse eventsBuprenorphine group
2025
Differences in Diagnosis and Treatment Across Racial-Ethnic Groups with Co-Occurring Chronic Pain and Opioid Use Disorder: A Scoping Review
Nunes J, Costa G, Cerezo-Matias M, Funaro M, Campbell C, De Aquino J. Differences in Diagnosis and Treatment Across Racial-Ethnic Groups with Co-Occurring Chronic Pain and Opioid Use Disorder: A Scoping Review. Pain Medicine 2025, pnaf173. PMID: 41358971, DOI: 10.1093/pm/pnaf173.Peer-Reviewed Original ResearchConceptsChronic non-cancer painOpioid use disorderScoping ReviewMixed Methods Appraisal ToolNon-pharmacological pain treatmentsMethods Appraisal ToolNon-whitePatient-reported experiencesRisk of opioid misusePain-related distressOpioid use disorder diagnosisProvider decision-makingPRISMA-ScR guidelinesOpioid use disorder careOpioid prescribing ratesNon-cancer painRacial-ethnic differencesAccess-related factorsHigh riskUse disorderManagement of individualsRacial-ethnic groupsTreatment access barriersIntegrated careNon-white individualsExpanding Access to Buprenorphine and Methadone: Global Perspectives and Policy Recommendations.
Nunes J, Costa G, De Aquino J, Adinoff B. Expanding Access to Buprenorphine and Methadone: Global Perspectives and Policy Recommendations. Substance Use & Addiction Journal 2025, 29767342251392342. PMID: 41317155, DOI: 10.1177/29767342251392342.Peer-Reviewed Original ResearchConceptsNarrative review of peer-reviewedPolicy literaturePolicy recommendationsOverdose deathsUniversal coverageMOUD accessPolicyRegulatory reformPublic health systemNational scale-upEconomic gainsReview of peer-reviewedOpioid use disorderNarrative reviewGlobal burdenInternational evidenceU.S. coverageNational prevalence dataOpioid-related deathsCenters for Disease ControlHealth systemMortality dataRegulatory bottlenecksGlobal Burden of Disease StudyMainstream healthcareContingency management for unhealthy alcohol use: A systematic review and meta‐analysis
Alessi M, dos Santos Barbetta L, Andreata V, Leal A, Freitas R, Costa G, Nero N, Anand A. Contingency management for unhealthy alcohol use: A systematic review and meta‐analysis. Alcohol Clinical And Experimental Research 2025, 49: 2660-2674. PMID: 41261929, DOI: 10.1111/acer.70198.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsUnhealthy alcohol useAlcohol use disorderContingency managementAlcohol useSystematic reviewMeta-analysisUse disorderClinical utilityAlcohol consumptionGeneric inverse variance methodSevere alcohol use disorderTreatment of alcohol-related problemsMeasures of alcohol useSelf-reported alcohol consumptionNon-contingent rewardsInverse variance methodAlcohol-free daysTreatment-as-usualSubstance use disordersNon-randomized trialsROBINS-I toolAlcohol-related problemsRisk of biasEvidence-based approachConcurrent nicotineReadability, linguistic complexity, and stigma in ChatGPT responses to opioid use disorder FAQs: A comparative analysis
Campos V, Heringer D, Costa G, Oliva H, Anand A. Readability, linguistic complexity, and stigma in ChatGPT responses to opioid use disorder FAQs: A comparative analysis. American Journal On Addictions 2025 PMID: 41189042, DOI: 10.1111/ajad.70101.Peer-Reviewed Original Research135. Bridging Psychiatry and Endocrinology: A Case Report on Pheochromocytoma With Severe Medication Anxiety
Collins A, Heringer D, Costa G, Burns N. 135. Bridging Psychiatry and Endocrinology: A Case Report on Pheochromocytoma With Severe Medication Anxiety. Journal Of The Academy Of Consultation-Liaison Psychiatry 2025, 66: s115. DOI: 10.1016/j.jaclp.2025.10.137.Peer-Reviewed Original ResearchConceptsTobacco use Disorder and Chronic Pain: a Narrative Review of Integrated Treatment Approaches, Underlying Mechanisms, and Future Research Directions
da Rocha L, Costa G, Sofuoglu M, Castaldelli-Maia J, De Aquino J. Tobacco use Disorder and Chronic Pain: a Narrative Review of Integrated Treatment Approaches, Underlying Mechanisms, and Future Research Directions. Current Addiction Reports 2025, 12: 75. DOI: 10.1007/s40429-025-00687-y.Peer-Reviewed Original ResearchConceptsIntegrated treatment approachBrief motivational interventionChronic painEcological momentary assessmentEvidence-based careMethodological limitationsTobacco use disorderNarrative reviewHigh co-occurrenceTreatment approachesWell-powered randomized controlled trialsRandomized Controlled TrialsMomentary assessmentMood benefitsMotivational interventionUse disorderAdvanced careSmoking relapseOutcome expectationsTobacco useSmoking cessationPain managementPain-related stressEvidence baseFollow-up periodTobacco–cannabis co‐use in adults ≥50: Trends, medical marijuana laws, and cessation implications—Letter to the Editor
Costa G, Asnes S, De Aquino J. Tobacco–cannabis co‐use in adults ≥50: Trends, medical marijuana laws, and cessation implications—Letter to the Editor. American Journal On Addictions 2025, 34: 682-683. PMID: 41025258, DOI: 10.1111/ajad.70088.Peer-Reviewed Original ResearchQuantitative sensory testing of pain in persons with opioid use disorder on opioid agonist treatment: a scoping review
Oliveira D, Costa G, Fontenele R, Córdoba-Delgado M, Funaro M, Campbell C, Fiellin D, Angarita G, De Aquino J. Quantitative sensory testing of pain in persons with opioid use disorder on opioid agonist treatment: a scoping review. Pain Medicine 2025, pnaf132. PMID: 40990827, DOI: 10.1093/pm/pnaf132.Peer-Reviewed Original ResearchConceptsQuantitative sensory testingOpioid use disorderOpioid agonist treatmentQST measuresAgonist treatmentQuantitative sensory testing methodologyQuantitative sensory testing outcomesUse disorderNon-OAT opioidsPain processing abnormalitiesPain sensitivity changesPain-related outcomesCold pain toleranceCentral sensitizationSystematic literature searchPain mechanismsPain modulationNeuroadaptive changesPain responseChronic painTreatment responseProlonged abstinencePainWeb of ScienceOpioidImpact of X-Waiver Elimination on Post-Hospital Discharge Buprenorphine Prescribing: An Interrupted Time Series Analysis.
Wang PR, Mascha EJ, Li Y, Bobak L, Dorney I, Costa G, Barnett B, Anand A. Impact of X-Waiver Elimination on Post-Hospital Discharge Buprenorphine Prescribing: An Interrupted Time Series Analysis. J Addict Med 2025 PMID: 40794490, DOI: 10.1097/ADM.0000000000001568.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Copy Link
Honors
honor Early Career Investigator
04/07/2025National AwardCollege on Problems of Drug Dependencehonor John Renner Travel Award
01/07/2024National AwardAmerican Academy of Addiction Psychiatry
News & Links
Copy Link
News
- December 02, 2025
Expanding Access to Buprenorphine and Methadone: Global Perspectives and Policy Recommendations
- October 15, 2025Source: Current Addiction Reports
Tobacco Use Disorder and Chronic Pain: A Narrative Review of Integrated Treatment Approaches, Underlying Mechanisms, and Future Research Directions
- September 25, 2025Source: Pain Medicine
Quantitative Sensory Testing of Pain in Persons with Opioid Use Disorder on Opioid Agonist Treatment: A Scoping Review
- August 11, 2025Source: Drug and Alcohol Dependence
Cannabis Use Frequency is Associated with Emotion Dysregulation Among Persons Receiving Long-Term Opioid Therapy for Chronic Pain
Related Links
Get In Touch
Copy Link